News Releases

Date	Title
09/29/20	New Peer-Reviewed Data Highlight the Benefits of XHANCE in Patients Who Remain Symptomatic After Treatment with Standard Nasal Steroid Sprays
09/14/20	Optinose to Present at the Cantor Virtual Global Healthcare Conference
08/14/20	Optinose Announces Pricing of Public Offering of Common Stock
08/13/20	Optinose Announces Proposed Public Offering of Common Stock
08/04/20	Optinose Reports Second Quarter 2020 Financial Results and Recent Operational Highlights
07/30/20	Optinose Announces Reporting Date for Second Quarter 2020 Financial Results
07/29/20	Optinose names Catherine E. Owen as Director
07/08/20	Optinose Announces XHANCE Co-Promotion Agreement with Kaléo
06/30/20	Optinose Announces Anti-COVID-19 Product Candidate
06/22/20	Optinose to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
06/19/20	Optinose Named a 2020 Best Place to Work by Philadelphia Business Journal
05/27/20	Optinose to Host its Annual Meeting of Stockholders in Virtual Format
05/26/20	Optinose to Present at the 2020 Jefferies Virtual Healthcare Conference
05/14/20	Optinose to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
05/07/20	Optinose Reports First Quarter 2020 Financial Results and Operational Updates
04/30/20	Optinose to Report First Quarter 2020 Financial Results and Corporate Updates on May 7, 2020
03/05/20	Optinose Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Operational Highlights
02/27/20	Optinose to Report Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates on March 5, 2020
02/19/20	Optinose Appoints Victor Clavelli as Chief Commercial Officer

News Releases

News Releases

Investors

Toolkit

Investor Contact

News Releases

News Releases

Keyword Search

Investors

Toolkit

Investor Contact